Literature DB >> 8344700

Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG.

U G Andersson1, L Björk, U Skansén-Saphir, J P Andersson.   

Abstract

The influence of pooled human IgG preparations for intravenous use (i.v.Ig) on in vitro-induced cytokine production was studied at the single-cell level using cytokine-specific monoclonal antibodies (mAb) and indirect immunofluorescent technique. Cultured mononuclear cells from peripheral blood from healthy adult donors were polyclonally stimulated for 96 hr by either direct ligation of T-cell receptors using immobilized anti-CD3 mAb or by a combination of a protein kinase C activator [phorbol 12-myristate 13-acetate (PMA)] and a calcium ionophore (ionomycin) in the absence or presence of i.v.Ig. A marked inhibition of proliferation and blast transformation was noted in all i.v.Ig exposed cultures, despite good cell survival. The production of the T-cell lymphokines interleukin-2 (IL-2), IL-10,interferon-gamma (IFN-gamma) and tumour necrosis factor-beta (TNF-beta) was significantly down-regulated during the whole studied period in the i.v.Ig containing anti-CD3 stimulated cultures. The synthesis of the monokine IL-8 was not suppressed and that of TNF-alpha, which was made by both lymphocytes and monocytes, was only moderately inhibited. Somewhat different and more transient effects were observed in the i.v.Ig-exposed PMA/ionomycin-activated cultures. The production of IL-2, IL-3, IL-4, IL-5, IL-10, TNF-beta and granulocyte-macrophage colony-stimulating factor (GM-CSF) was down-regulated during the initial phase of the cultures up to 48 hr, but not at 48-96 hr. The synthesis of IFN-gamma and TNF-alpha was unaffected of the influence of i.v.Ig during the entire culture period. The expression of IL-2 receptors (IL-2R) was significantly suppressed in the i.v.Ig-treated anti-CD3-activated cells, but not in the PMA/ionomycin-stimulated cultures. Taken together our results indicate that pooled IgG may mediate immunomodulation by direct effects on cytokine production and on T-cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8344700      PMCID: PMC1421866     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

Review 1.  Bacterial toxin-induced cytokine production studied at the single-cell level.

Authors:  J Andersson; S Nagy; L Björk; J Abrams; S Holm; U Andersson
Journal:  Immunol Rev       Date:  1992-06       Impact factor: 12.988

2.  Human intravenous immunoglobulin modulates monokine production in vitro.

Authors:  J P Andersson; U G Andersson
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

3.  Simultaneous production of interleukin 2, interleukin 4 and interferon-gamma by activated human blood lymphocytes.

Authors:  U Andersson; J Andersson; A Lindfors; K Wagner; G Möller; C H Heusser
Journal:  Eur J Immunol       Date:  1990-07       Impact factor: 5.532

4.  Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states.

Authors:  A Montanaro; B Pirofsky
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

5.  Highly sensitive enzyme immunoassays for antibodies to human tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta).

Authors:  H R Lamche; G R Adolf
Journal:  J Immunol Methods       Date:  1990-08-07       Impact factor: 2.303

6.  Monoclonal antibody two-site ELISA for human IFN-gamma. Adaptation for determinations in human serum or plasma.

Authors:  G Andersson; H P Ekre; G Alm; P Perlmann
Journal:  J Immunol Methods       Date:  1989-12-20       Impact factor: 2.303

7.  Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use.

Authors:  T Shimozato; M Iwata; N Tamura
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

8.  A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG.

Authors:  K H Roux; D L Tankersley
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

9.  Frequency analysis of lymphokine-secreting CD4+ and CD8+ T cells activated in a graft-versus-host reaction.

Authors:  A Kelso
Journal:  J Immunol       Date:  1990-10-01       Impact factor: 5.422

10.  Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease.

Authors:  D Y Leung; R S Cotran; E Kurt-Jones; J C Burns; J W Newburger; J S Pober
Journal:  Lancet       Date:  1989-12-02       Impact factor: 79.321

View more
  25 in total

1.  Natural antibody-induced intracellular signalling and growth control in C3H 10T1/2 fibroblast variants.

Authors:  H Wang; D A Chow
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

Review 2.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

Review 4.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 5.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

6.  Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.

Authors:  Sevim Barbasso Helmers; Maryam Dastmalchi; Helene Alexanderson; Inger Nennesmo; Mona Esbjörnsson; Björn Lindvall; Ingrid E Lundberg
Journal:  Ann Rheum Dis       Date:  2007-02-02       Impact factor: 19.103

7.  Neuroinflammatory Nexus of Pediatric Epilepsy.

Authors:  Shruti Bagla; Alan A Dombkowski
Journal:  J Pediatr Epilepsy       Date:  2018-09-03

Review 8.  Criteria for the appropriate drug utilisation of immunoglobulin.

Authors:  P Thürmann; S Harder
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

9.  Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD).

Authors:  Y Takata; S Seki; H Dobashi; S Takeshita; K Nakatani; Y Kamezawa; H Hiraide; I Sekine; S Yoshioka
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 10.  Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors:  J Nicholas Brenton; Brenda L Banwell
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.